Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Apr 25;45(3):639-646.
doi: 10.1093/schbul/sby095.

How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials

Affiliations
Meta-Analysis

How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials

Myrto T Samara et al. Schizophr Bull. .

Abstract

Objective: An important clinical question is how many patients with acute schizophrenia do not respond to antipsychotics despite being treated for adequate time and with an effective dose. However, up to date, the exact extent of the phenomenon remains unclear.

Methods: We calculated the nonresponse and nonremission percentages using individual patient data from 16 randomized controlled trials (RCTs). Six thousand two hundred twenty-one patients were assigned to one antipsychotic (amisulpride, flupenthixol, haloperidol, olanzapine, quetiapine, risperidone, or ziprasidone) at an adequate dose; the response was assessed at 4-6 weeks. As various definitions of nonresponse have been used in the literature, we applied 4 different cut-offs covering the whole range of percent Positive and Negative Syndrome Scale (PANSS)/Brief Psychiatric Rating Scale (BPRS) reduction (≤0%, <25%, <50%, <75%).For symptomatic remission, we used the definition proposed by Andreasen without employing the time criterion.

Results: The overall nonresponse for the cut-off of ≤0% PANSS/BPRS reduction was 19.8% (18.8%-20.8%); for the cut-off of <25% reduction it was 43% (41.7%-44.3%); for the cut-off of <50% reduction it was 66.5% (65.3%-67.8%); and for the cut-off of <75% reduction it was 87% (86%-87.9%). The overall percentage of no symptomatic remission was 66.9% (65.7%-68.1%). Earlier onset of illness, lower baseline severity and the antipsychotic used were significantly associated with higher nonresponse percentages.

Conclusions: Nonresponse and nonremission percentages were notably high. Nevertheless, the patients in our analysis could represent a negative selection since they came from short-term RCTs and could have been treated before study inclusion; thus, further response may not have been observed. Observational studies on this important question are needed.

Keywords: neuroleptic; nonremission; nonresponse; unresponsive.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall frequency of nonresponse and nonremission. The first 4 bars display the overall frequency of nonresponse according to the following criteria of nonresponse: ≤0%, <25%, <50%, and <75% PANSS/BPRS total score reduction. The fifth bar displays the overall frequency of nonremission according to Andreasen criteria. The error bars display the 95% confidence intervals.

References

    1. Lehman AF, Lieberman JA, Dixon LB, et al. . Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 suppl):1–56. - PubMed
    1. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull. 1988;24:62–67. - PubMed
    1. Brenner HD, Dencker SJ, Goldstein MJ, et al. . Defining treatment refractoriness in schizophrenia. Schizophr Bull. 1990;16:551–561. - PubMed
    1. Remington G, Chong SA. Conventional versus novel antipsychotics: changing concepts and clinical implications. J Psychiatry Neurosci. 1999;24:431–441. - PMC - PubMed
    1. Lindenmayer JP, Khan A. Assessment of therapy-resistant schizophrenia. In: Elkis H, Meltzer HY, eds. Therapy-Resistant Schizophrenia. Vol 26 Basel: Karger; 2010:9–32.

Publication types

MeSH terms

Substances